Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Authors

Lillian L. Siu

Princess Margaret Cancer Centre, Toronto, ON, Canada

Lillian L. Siu , Kyriakos P. Papadopoulos , Frank Yung-Chin Tsai , Aaron Richard Hansen , Paul B. Robbins , Xia Li , Dominic W Lai , John A. Blake-Haskins , Matthew G. Fury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

First Author: Neil Howard Segal

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

First Author: Tanguy Y. Seiwert

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530).

First Author: Dan Paul Zandberg

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.

First Author: Steven Francis Powell